Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...